Table 2.
Results of the analysis of co-variance testing for the effects of each group (patients vs. healthy controls) and a history of ACEs on the metabolic parameters after co-varying for potential confounding factors.
| Glucose | Insulin | HOMA-IR | LDL | HDL | TC | Triglycerides | hsCRP | |
|---|---|---|---|---|---|---|---|---|
| Group |
F = 4.856
p = 0.030 |
F = 1.585 p = 0.245 |
F = 3.847 p = 0.053 |
F = 0.025 p = 0.875 |
F = 5.300
p = 0.023 |
F = 0.008 p = 0.928 |
F = 4.720
p = 0.032 |
F = 7.499
p = 0.007 |
| ACEs | F = 0.352 p = 0.554 |
F = 5.960
p = 0.016 |
F = 5.586
p = 0.020 |
F = 0.753 p = 0.388 |
F < 0.001 p = 0.985 |
F = 0.896 p = 0.346 |
F = 1.688 p = 0.197 |
F = 0.004 p = 0.947 |
| Group × ACEs | F = 0.266 p = 0.607 |
F = 4.497
p = 0.036 |
F = 3.987
p = 0.048 |
F = 0.214 p = 0.645 |
F = 0.001 p = 0.972 |
F = 0.886 p = 0.349 |
F = 1.547 p = 0.217 |
F = 0.210 p = 0.647 |
| Age |
F = 4.623
p = 0.034 |
F = 0.454 p = 0.502 |
F = 0.087 p = 0.769 |
F = 21.688
p < 0.001 |
F = 0.151 p = 0.699 |
F = 22.183
p < 0.001 |
F = 2.768 p = 0.099 |
F = 0.045 p = 0.832 |
| Sex | F = 0.001 p = 0.977 |
F = 1.917 p = 0.169 |
F = 1.289 p = 0.259 |
F = 0.341 p = 0.561 |
F = 4.094
p = 0.046 |
F = 0.051 p = 0.822 |
F = 2.955 p = 0.089 |
F = 0.361 p = 0.549 |
| BMI | F = 1.013 p = 0.317 |
F = 0.589 p = 0.445 |
F = 0.814 p = 0.369 |
F = 1.761 p = 0.188 |
F = 12.002
p = 0.001 |
F = 0.081 p = 0.777 |
F = 6.547
p = 0.012 |
F = 0.848 p = 0.359 |
| CPZeq | F = 0.954 p = 0.331 |
F = 0.052 p = 0.821 |
F = 0.004 p = 0.951 |
F = 2.371 p = 0.127 |
F = 0.009 p = 0.923 |
F = 3.254 p = 0.074 |
F = 2.606 p = 0.110 |
F = 4.047
p = 0.047 |
| Illness duration | F = 0.073 p = 0.787 |
F = 0.010 p = 0.920 |
F = 0.006 p = 0.937 |
F = 9.096
p = 0.003 |
F = 0.020 p = 0.888 |
F = 7.628
p = 0.007 |
F = 0.005 p = 0.945 |
F = 4.425
p = 0.038 |
| Cigarette smoking | F = 0.001 p = 0.973 |
F = 0.075 p = 0.785 |
F = 0.168 p = 0.683 |
F = 0.475 p = 0.492 |
F = 2.240 p = 0.138 |
F = 1.620 p = 0.206 |
F = 0.012 p = 0.912 |
F = 1.535 p = 0.218 |
ACEs, adverse childhood experiences; BMI, body mass index; CPZeq, chlorpromazine equivalent dosage; hsCRP, high-sensitivity C-reactive protein; HDL, high density lipoproteins; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low density lipoproteins; TC, total cholesterol. Significant effects (p < 0.05) were marked with bold characters.